NASDAQ:SBTX Silverback Therapeutics (SBTX) Stock Price, News & Analysis $4.05 -0.13 (-3.11%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Silverback Therapeutics Stock (NASDAQ:SBTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SBTX alerts:Sign Up Key Stats Today's Range$4.00▼$4.1850-Day Range$4.07▼$6.3052-Week Range$2.80▼$8.97Volume1.55 million shsAverage Volume337,931 shsMarket Capitalization$146.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Silverback Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing targeted medicines for cancer and other serious diseases. The company’s research centered on its ImmunoTAC platform, which was designed to use antibody-based targeting to deliver immune-modulating payloads to specific tissues and disease sites. Silverback developed a pipeline of investigational programs intended to address conditions involving the immune system, including oncology and fibrotic diseases. Its approach sought to improve the precision of treatment by concentrating therapeutic activity in diseased tissues while limiting exposure to healthy tissue. The company’s programs remained in development and were not broadly marketed products. In 2022, Silverback Therapeutics combined with ARS Pharmaceuticals in a reverse merger. The combined company adopted the ARS Pharmaceuticals name and continued under the Nasdaq ticker SPRY, meaning Silverback is no longer an independently traded company. Public information about Silverback’s former leadership and operations primarily relates to its period as a standalone biotechnology company headquartered in the United States.AI Generated. May Contain Errors. Read More Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBTX Stock News HeadlinesARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.October 14 at 1:00 AM | Monument Traders Alliance (Ad)ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comSee More Headlines SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed this year? Silverback Therapeutics' stock was trading at $11.72 at the beginning of the year. Since then, SBTX stock has decreased by 65.4% and is now trading at $4.05. How were Silverback Therapeutics' earnings last quarter? Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). When did Silverback Therapeutics IPO? Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager. How do I buy shares of Silverback Therapeutics? Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2021Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SBTX CIK1671858 Webwww.silverbacktx.com Phone206 456 2900FaxN/AEmployees83Year Founded2016Profitability EPS (Trailing Twelve Months)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.62% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio67.87 Quick Ratio67.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book0.55Miscellaneous Outstanding Shares36,058,000Free Float23,654,000Market Cap$146.03 million OptionableNot Optionable Beta0.60 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SBTX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
